NCT01121848 - Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Pancreatic Neoplasms

Interventions

DRUG

Leucovorin

"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"

DRUG

OXALIPLATIN

"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"

DRUG

5-Fluorouracil

"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"

Trial Locations (15)

V2S0C2

Investigational Site Number 124015, Abbotsford

L6V1B4

Investigational Site Number 124018, Brampton

V5G2X6

Investigational Site Number 124014, Burnaby

T2N 4N2

Investigational Site Number 124006, Calgary

P3E5J1

Investigational Site Number 124008, Greater Sudbury

J4V2H1

Investigational Site Number 124011, Greenfield Park

L8V5C2

Investigational Site Number 124010, Hamilton

Unknown

Investigational Site Number 124-016, New Glasgow

L1G2B9

Investigational Site Number 124013, Oshawa

K1Y0W9

Investigational Site Number 124012, Ottawa

J1H 5N4

Investigational Site Number 124004, Sherbrooke

V3V1Z2

Investigational Site Number 124007, Surrey

M4N3M5

Investigational Site Number 124003, Toronto

M5G2M9

Investigational Site Number 124002, Toronto

N5Z4E6

Investigational Site Number 124001, Vancouver